---
title: "This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290836066.md"
description: "Wall Street analysts initiated coverage on several stocks this Thursday. Key initiations include Raymond James giving Tonix Pharmaceuticals (TNXP) a Strong Buy with a $26 target, BTIG rating Boost Run (BRUN) as Buy with a $45 target, and Roth Capital assigning Castle Biosciences (CSTL) a Buy with a $40 target. Goldman Sachs initiated Intel (INTC) at Neutral ($150), while Keefe, Bruyette & Woods rated Arrow Financial (AROW) Market Perform ($42)."
datetime: "2026-06-25T12:44:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290836066.md)
  - [en](https://longbridge.com/en/news/290836066.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290836066.md)
generator: "portal-rs"
---

# This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

-   Goldman Sachs analyst James Schneider initiated coverage on **Intel Corp** (NASDAQ:INTC) with a Neutral rating and announced a price target of $150. Intel shares closed at $131.91 on Wednesday. See how other analysts view this stock.
-   Keefe, Bruyette & Woods analyst Damon Delmonte initiated coverage on **Arrow Financial Corp** (NASDAQ:AROW) with a Market Perform rating and announced a price target of $42. Arrow Financial shares closed at $40.36 on Wednesday. See how other analysts view this stock.
-   BTIG analyst Gregory Lewis initiated coverage on **Boost Run Inc** (NASDAQ:BRUN) with a Buy rating and announced a price target of $45. Boost Run shares closed at $34.26 on Wednesday. See how other analysts view this stock.
-   Raymond James analyst Tiago Fauth initiated coverage on **Tonix Pharmaceuticals Holding Corp** (NASDAQ:TNXP) with a Strong Buy rating and announced a price target of $26. Tonix Pharmaceuticals shares closed at $12.10 on Wednesday. See how other analysts view this stock.
-   Roth Capital analyst Max Masucci initiated coverage on **Castle Biosciences Inc** (NASDAQ:CSTL) with a Buy rating and announced a price target of $40. Castle Biosciences shares closed at $22.12 on Wednesday. See how other analysts view this stock.

Considering buying TNXP stock? Here’s what analysts think:

*Photo via Shutterstock*

### Related Stocks

- [TNXP.US](https://longbridge.com/en/quote/TNXP.US.md)
- [CSTL.US](https://longbridge.com/en/quote/CSTL.US.md)
- [BRUN.US](https://longbridge.com/en/quote/BRUN.US.md)
- [INTC.US](https://longbridge.com/en/quote/INTC.US.md)
- [AROW.US](https://longbridge.com/en/quote/AROW.US.md)
- [04335.HK](https://longbridge.com/en/quote/04335.HK.md)
- [INTW.US](https://longbridge.com/en/quote/INTW.US.md)
- [LINT.US](https://longbridge.com/en/quote/LINT.US.md)
- [INYY.US](https://longbridge.com/en/quote/INYY.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [RJF.US](https://longbridge.com/en/quote/RJF.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)
- [RJF-B.US](https://longbridge.com/en/quote/RJF-B.US.md)

## Related News & Research

- [Intel Stock (INTC) Sweeps the Board as U.S. Chess Champion Celebrates Portfolio's First Birthday](https://longbridge.com/en/news/298210297.md)
- [Report Says Intel Corporation  to Raise PC CPU Prices by Another 10% Next Month](https://longbridge.com/en/news/298241069.md)
- [This Arrow Financial Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday](https://longbridge.com/en/news/297785990.md)
- [Tonix highlights TONMYA fibromyalgia launch, pipeline progress in investor presentation](https://longbridge.com/en/news/297923504.md)
- [Acer: AI-powered devices, modular eco-friendly laptops, and gaming innovations led a milestone event](https://longbridge.com/en/news/297783692.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**